What is the optimal duration of adjuvant therapy for colon cancer?

Updated: Apr 15, 2020
  • Author: Tomislav Dragovich, MD, PhD; Chief Editor: N Joseph Espat, MD, MS, FACS  more...
  • Print
Answer

In the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) trial (n=12,834), which compared 3 versus 6 months of FOLFOX or CapeOx, 3-year disease-free survival (DFS) in the FOLFOX 3-month arm was lower than that in the 6-month arm by 0.9% (hazard ratio [HR], 1.07; 95% confidence interval [CI], 1.00 - 1.15). To meet the prespecified noninferiority threshold, the upper limit of the 95% CI had to be 1.12 or less, so noninferiority was not established. 

However, shorter therapy was associated with significantly less neurotoxicity. Rates of neurotoxicity were 17% versus 48% with 3 versus 6 months, respectively, of FOLFOX; comparable figures with CapeOx were15% and 45%, respectively; P < 0.0001). [92]


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!